Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study (vol 56, pg 770, 2020)

被引：0
|
作者：
Zamarin, Dmitriy
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2702 / 2702
页数：1
相关论文
共 50 条
  • [1] 1 Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
    Zamarin, Dmitriy
    Burger, Robert A.
    Sill, Michael W.
    Powell, Daniel J., Jr.
    Lankes, Heather A.
    Feldman, Michael D.
    Zivanovic, Oliver
    Gunderson, Camille
    Ko, Emily
    Mathews, Cara
    Sharma, Sudarshan
    Hagemann, Andrea R.
    Khleif, Samir
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1814 - +
  • [2] NRG ONCOLOGY PHASE II RANDOMIZED TRIAL OF NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN CANCER
    Burger, R.
    Sill, M.
    Zamarin, D.
    Powell, D.
    Frak, I.
    Zivanovic, O.
    Gunderson, C.
    Ko, E.
    Mathews, C.
    Sharma, S.
    Hagemann, A.
    Khleif, S.
    Aghajanian, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 19 - 19
  • [3] A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
    Lheureux, Stephanie
    Matei, Daniela
    Konstantinopoulos, Panagiotis A.
    Block, Matthew Stephen
    Jewell, Andrea
    Gaillard, Stephanie
    McHale, Michael S.
    McCourt, Carolyn K.
    Temkin, Sarah
    Girda, Eugenia
    Backes, Floor Jenniskens
    Werner, Theresa Louise
    Duska, Linda R.
    Kehoe, Siobhan Marie
    Wang, Lisa
    Wildman, Rachel
    Wang, Ben X.
    Ohashi, Pamela S.
    Wright, John Joseph
    Fleming, Gini F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
    Pouyiourou, Maria
    Kraft, Bianca N.
    Wohlfromm, Timothy
    Stahl, Michael
    Kubuschok, Boris
    Loeffler, Harald
    Hacker, Ulrich T.
    Huebner, Gerdt
    Weiss, Lena
    Bitzer, Michael
    Ernst, Thomas
    Schuett, Philipp
    Hielscher, Thomas
    Delorme, Stefan
    Kirchner, Martina
    Kazdal, Daniel
    Ball, Markus
    Kluck, Klaus
    Stenzinger, Albrecht
    Bochtler, Tilmann
    Kraemer, Alwin
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [5] Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
    Maria Pouyiourou
    Bianca N. Kraft
    Timothy Wohlfromm
    Michael Stahl
    Boris Kubuschok
    Harald Löffler
    Ulrich T. Hacker
    Gerdt Hübner
    Lena Weiss
    Michael Bitzer
    Thomas Ernst
    Philipp Schütt
    Thomas Hielscher
    Stefan Delorme
    Martina Kirchner
    Daniel Kazdal
    Markus Ball
    Klaus Kluck
    Albrecht Stenzinger
    Tilmann Bochtler
    Alwin Krämer
    Nature Communications, 14
  • [6] A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
    Liu, J. F.
    Herold, C.
    Luo, W.
    Penson, R.
    Horowitz, N.
    Konstantinopoulos, P.
    Castro, C.
    Curtis, J.
    Matulonis, U. A.
    Cannistra, S.
    Dizon, D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).
    Singh, Arun S.
    Chmielowski, Bartosz
    Hecht, J. Randolph
    Rosen, Lee S.
    Chow, Warren Allen
    Wang, Xiaoyan
    Brackert, Sandra
    Adame, Carlos
    Bovill, John
    Schink, Elena
    Douek, Michael
    Chantharasamee, Jomjit
    Wong, Karlton
    Eilber, Frederick C.
    Glaspy, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] A phase II trial of brivanib in recurrent or persistent enclometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Powell, Matthew A.
    Sill, Michael W.
    Goodfellow, Paul J.
    Benbrook, Doris M.
    Lankes, Heather A.
    Leslie, Kimberly K.
    Jeske, Yvette
    Mannel, Robert S.
    Spillman, Monique A.
    Lee, Paula S.
    Hoffman, James S.
    McMeekin, D. Scott
    Pollock, Pamela M.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 38 - 43
  • [9] Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
    Tew, William P.
    Sill, Michael W.
    Walker, Joan L.
    Secord, Angeles Alvarez
    Bonebrake, Albert J.
    Schilder, Jeanne M.
    Stuckey, Ashley
    Rice, Laurel
    Tewari, Krishnansu S.
    Aghajanian, Carol A.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 257 - 263
  • [10] Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Burger, Robert A.
    Deng, Wei
    Makker, Vicky
    Collins, Yvonne
    Gray, Heidi
    Debernardo, Robert
    Martin, Lainie P.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 466 - 470
12345